Daga Mustapha Abdullahi
Hukumar kula da ingancin abinci da magunguna ta ƙasa, NAFDAC, ta yi gargadi ga ‘yan Najeriya kan yaduwar wasu jabun magungunan cutar kansa guda biyu , Avastin da Tecentriq , a cikin ƙasar kamar yadda jaridar TheCable ta rawaito.
A cewar hukumar, maganin Avastin (bevacizumab) ana amfani da shi wajen magance cutar ƙwaƙwalwa mai tsanani (glioblastoma) ga manya, yayin da Tecentriq (atezolizumab) magani ne na ƙarfafa garkuwar jiki (immunotherapy) da ake amfani da shi wajen jinyar nau’o’in cutar kansa daban-daban da suka haɗa da kansar huhu, hanta da fata.
A cikin wata sanarwar gaggawa da ta fitar, NAFDAC ta ce ta tabbatar da cewa akwai wasu jabun samfurorin Avastin 400mg/16ml da Tecentriq 1200mg/20ml da ke yawo a kasuwannin Najeriya.
Hukumar ta bayyana cewa wannan gargadi ya biyo bayan bayanai da ta samu daga kamfanin Roche Nigeria, wanda ya tabbatar da samun koke-koke daga ma’aikatan lafiya a sassa daban-daban na ƙasar kan waɗannan magunguna.
A wasu lokuta, marasa lafiya ne ke kai magungunan da ake zargi jabun ne zuwa asibitoci, inda aka gano cewa ana sayar da su a farashi mai rahusa sosai, tsakanin naira 180,000 zuwa 350,000.
Binciken da aka gudanar ya nuna bambance-bambance da dama tsakanin magungunan na gaske da na jabu, ciki har da lambobin rukuni (batch numbers) da ba su dace ba, ƙarancin ingancin bugu da zane, kuskuren rubutu, da kuma rashin daidaiton lambobin sirri da alamar kariya ta samfur (tamper-evident labels).
NAFDAC ta kuma lissafo wasu lambobin rukuni na jabun magungunan Avastin da suka haɗa da H4239A70, H2290A34, da A3508B02, da kuma na Tecentriq mai lamba B3071A12.
Sai dai hukumar ta ce ba ta samu damar yin cikakken gwajin sinadarai kan magungunan ba, domin binciken ya dogara ne kan hotunan kunshin magungunan da aka aiko mata, ba tare da samun samfurori a zahiri ba.